Main Article Content

Abstract

The Levocetirizinedihydrochloride is a third-generation, non-sedating antihistamine, developed from the second generation antihistamine cetirizine. Chemically, levocetirizine is simply the isolated levorotary enantiomer of cetirizine. Concentrations of Levocetirizinedihydrochloride in serum and dialysate were determined by HPLC. The maximum serum Levocetirizinedihydrochloride concentration and the time to reach that maximum were 204 µg-1 and 0.75 hr, respectively. The terminal disposition half-life of Levocetirizinedihydrochloride in these patients was 8.3 hrs. The haemodialysis clearance of Levocetirizine was 11.0 ml/min-1. Although this is approximately 27% of the apparent total body clearance of Levocetirizinedihydrochloride in subjects with normal renal function, the fraction of the dose removed by dialysis was only 7.2%. Thus, since haemodialysis does not produce a clinically significantly alteration in Levocetirizinedihydrochloride elimination, no supplemental dose should be necessary after dialysis.

Keywords

Levocetirizine Haemodialysis Pharmacokinetics Renal failure

Article Details

How to Cite
N. Sriram, S V Jahnavi Narayabhatla, N.Shiva Krishna, K.Nava Jyothi, & Hanumanth Srinivas. (2021). Clinical outcome of haemodialysis on the pharmacokinetics of levocetirizinedihydrochloride. International Journal of Research in Pharmacology & Pharmacotherapeutics, 7(4), 390-393. Retrieved from https://ijrpp.com/ijrpp/article/view/312

References

  1. [1]. Perzanowska M, Malhotra D, Skinner SP, Rihoux JP, Bewley AP, Petersen LJ, et al. The effect of cetirizine and loratadine on codeine-induced histamine release in human skin in vivo assessed by cutaneous microdialysis. Inflamm Res. 45, 1996, 486-90.
  2. [2]. Kamarapu SK, Vaijayanthi, Bahlul ZEA, Venisetty RK. Development of RP-HPLC method for the analysis of Levocetirizine.2Hcl and Ambroxol.Hcl in combination and its application. 3, 2010, 893- 896.
  3. [3]. Robinson BM, Joffe MM, Pisoni RL, Port FK, Feldman HI. Revisiting Survival Differences by Race and Ethnicity among Hemodialysis Patients: The Dialysis Outcomes and Practice Patterns Study. J Am SocNephrol. 17(10), 2006, 2910–18.
  4. [4]. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, et al. Serum Phosphate Levels and Mortality Risk among People with Chronic Kidney Disease. J Am SocNephrol. 16(2), 2005, 520–28.
  5. [5]. Geerts AF, Scherpbier-de Haan ND, de Koning FH, van der Sterren TM, van Weel C, Vervoort GM, et al. A pharmacy medication alert system based on renal function in older patients. Br J Gen Pract 62, 2012, e525–9.
  6. [6]. Kalender-Rich JL, Mahnken JD, Wetmore JB, Rigler SK. Transient impact of automated glomerular filtration rate reporting on drug dosing for hospitalized older adults with concealed renal insufficiency. Am J GeriatrPharmacother 9, 2011, 320–7.